Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mereo BioPharma Group plc (MREO)

1.31   -0.035 (-2.6%) 09-28 16:00
Open: 1.35 Pre. Close: 1.345
High: 1.36 Low: 1.29
Volume: 650,538 Market Cap: 169(M)

Technical analysis

as of: 2023-09-28 4:52:06 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 1.85     One year: 2.06
Support: Support1: 1.28    Support2: 1.07
Resistance: Resistance1: 1.58    Resistance2: 1.76
Pivot: 1.4
Moving Average: MA(5): 1.33     MA(20): 1.41
MA(100): 1.28     MA(250): 1.05
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 8.2     %D(3): 7.9
RSI: RSI(14): 43.6
52-week: High: 1.76  Low: 0.49
Average Vol(K): 3-Month: 900 (K)  10-Days: 463 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MREO ] has closed above bottom band by 20.4%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.36 - 1.37 1.37 - 1.37
Low: 1.27 - 1.28 1.28 - 1.29
Close: 1.3 - 1.31 1.31 - 1.32

Company Description

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Headline News

Thu, 28 Sep 2023
Does Mereo BioPharma Group plc - ADR (MREO) Have What it Takes to be in Your Portfolio Thursday? - InvestorsObserver

Thu, 21 Sep 2023
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference - Yahoo Finance

Mon, 18 Sep 2023
Where Will Mereo BioPharma Group plc - ADR (MREO) Stock Go Next After It Is Higher By 9.42% in a Week? - InvestorsObserver

Fri, 08 Sep 2023
Needham Reiterates Mereo Biopharma Group Plc - ADR (MREO ... - Nasdaq

Thu, 31 Aug 2023
Mereo Biopharma Group Plc - ADR (MREO) Price Target Increased ... - Nasdaq

Wed, 23 Aug 2023
Is Mereo BioPharma Group plc - ADR (MREO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 129 (M)
Shares Float 76 (M)
% Held by Insiders 0 (%)
% Held by Institutions 51 (%)
Shares Short 4,850 (K)
Shares Short P.Month 6,200 (K)

Stock Financials

EPS -0.29
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.46
Profit Margin (%) 0
Operating Margin (%) -444.3
Return on Assets (ttm) -21
Return on Equity (ttm) -41
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0.05
EBITDA (p.s.) -0.25
Qtrly Earnings Growth 0
Operating Cash Flow -33 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -4.68
PEG Ratio 0
Price to Book value 2.84
Price to Sales 23.63
Price to Cash Flow -5.07

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.